Angle’s Parsortix System Aids Important Findings Presented in Five Posters at AACR Annual Meeting April 16-20
Researchers’ use of ParsortixTM System for studies into multiple cancers confirms the cell separation technology’s ability to harvest viable circulating tumor cells for a broad range of downstream analyses
17 Apr 2016Angle plc announces that its Parsortix cell separation system will be featured in five different poster presentations at the American Association for Cancer Research Annual Meeting to be held April 16-20 in New Orleans.
The presentations, from researchers around the world, highlight the ability of Parsortix to effectively capture viable circulating tumor cells (CTCs) for downstream analysis to aid in the investigation of pancreatic, stage IV breast, bladder and lung cancers. One poster of note reported genomic differences between CTCs that have been isolated using the Parsortix size and deformability-based method and those that have been isolated using existing technology based on EpCAM affinity.
Presentation of the posters will occur at the following times:
Mon, Apr 18, 8:00 AM - 12:00 PM
Molecular profiling of circulating tumor cells as a surrogate for distant metastasis in stage IV breast cancer
Mon, Apr 18, 8:00 AM – 12:00 PM
Silencing of ERK2 reverses EMT and suppresses the CSC phenotype inhibiting lung metastasis in triplenegative breast cancer
Mon, Apr 18, 1:00 - 5:00 PM
Digital sorting and single-cell genomic profile comparison of lung adenocarcinoma CTCs between EpCAM and size-based enrichment methods
Tue, Apr 19, 8:00 AM - 12:00 PM
Circulating tumor cell enrichment and dielectric manipulation for ultra-pure cell recovery in advanced bladder cancer
Tue, Apr 19, 1:00 - 5:00 PM
Combined circulating tumot cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer
“The breadth of research represented in five presentations are testimony to the ability of the Parsortix system to serve as a valuable cell separation tool for researchers seeking to understand the mechanisms of various forms of cancer,” said Andrew Newland, CEO of ANGLE, plc. “We are excited that researchers across the globe continue to find our cell separation technology a useful tool to continue advancing the field of liquid biopsies.”
